Metagla

Methadone, the active ingredient in Metagla, is an opioid agonist presented as an oral formulation for oral use. It is employed in the management of opioid dependence and in the relief of severe chronic pain, providing long‑acting analgesia and reducing withdrawal symptoms in appropriate patients.

GNH USA supplies Metagla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and distribution. This ensures consistent product integrity across global markets.

Methadone acts on the opioid system and is indicated for the following clinical conditions: - Opioid dependence treatment: helps stabilize patients by reducing withdrawal symptoms and cravings during maintenance therapy. - Severe chronic pain: provides long‑acting analgesia for patients requiring continuous opioid control. - Detoxification from opioids: facilitates safe transition off short‑acting opioids under medical supervision. - Palliative care: offers effective pain relief for terminally ill patients when other opioids are insufficient.

Methadone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Constipation: reduced gastrointestinal motility leading to hard stools. - Nausea: feeling of sickness often accompanied by vomiting. - Drowsiness: increased sedation and reduced alertness. - Dry mouth: decreased salivary flow causing oral discomfort. - Sweating: excessive perspiration unrelated to temperature.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - QT interval prolongation: cardiac electrical disturbance increasing arrhythmia risk. - Severe hypotension: marked drop in blood pressure causing dizziness or fainting.

When prescribing methadone, clinicians should observe several safety precautions to minimize risk. - Assess renal and hepatic function: evaluate organ status before initiating therapy. - Monitor respiratory status: watch for signs of depression, especially after dose changes. - Evaluate cardiac risk: obtain baseline ECG to detect QT prolongation. - Avoid concurrent CNS depressants: limit use of alcohol, benzodiazepines, and barbiturates. - Use caution in pregnancy: limited data; weigh benefits against potential fetal risks. - Store at ambient temperature: keep in original container, protect from moisture and light.

Methadone interacts with several medicines; awareness of the interaction level guides clinical management.

Major Interactions (Avoid): - CNS depressants (e.g., benzodiazepines, alcohol): may cause profound respiratory depression. - MAO inhibitors: can precipitate severe hypotension or serotonin syndrome. - QT‑prolonging agents (e.g., certain antiarrhythmics): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): raise methadone plasma levels, requiring dose adjustment. - CYP3A4 inducers (e.g., rifampin): lower methadone concentrations, risking withdrawal. - Anticholinergic drugs: may exacerbate constipation and urinary retention.